Loading clinical trials...
Loading clinical trials...
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Effects of Enavogliflozin on Outcomes in Patients With Functional Tricuspid Regurgitation and Heart Failure With Preserved Left Ventricular Ejection Fraction
Conditions
Interventions
Enavogliflozin
Placebo
Locations
5
South Korea
Inha University Hospital
Incheon, South Korea
Asan Medical Center
Seoul, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Yonsei University Medical Center
Seoul, South Korea
Start Date
October 25, 2023
Primary Completion Date
June 1, 2027
Completion Date
August 1, 2027
Last Updated
December 29, 2025
NCT07083011
NCT07037459
NCT07197736
NCT07516145
NCT07464106
NCT07057466
Lead Sponsor
Asan Medical Center
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions